Could a shorter steroid course be just as good for HIV-Related pneumonia?
NCT ID NCT03856229
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a shortened steroid regimen (8 days for moderate, 14 days for severe pneumonia) against the standard 21-day course in 196 HIV patients with Pneumocystis pneumonia. The goal is to see if the shorter treatment is non-inferior in preventing death and complications. Participants must be on standard antibiotics and start steroids within 48 hours of admission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
prednisolone (or methylprednisolone equivalent)
What this could lead to
If successful, this could show that a shorter steroid course is just as effective, reducing side effects and simplifying treatment for HIV patients with this type of pneumonia.
What could go wrong
This is a non-inferiority trial, so it may only confirm that the shorter course is not worse, not necessarily better. The results may not apply to patients with other health conditions or those not on standard antibiotics.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro de Investigacion en Enfermedades Infecciosas
México, State of Mexico, 14080, Mexico